Zosano Pharma (NASDAQ:ZSAN) is an emerging lifesciences company that is developing novel treatments for diseases using its proprietary transdermal delivery platform. The company’s stock has been on a tear for the past week after announcing successful phase 3 results of M207, its transdermal patch for the treatment of acute moderate to severe migraine using a handheld applicator.
